GlobeNewswire: Jamieson Bondarenko Contains the last 10 of 4 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:56:25ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/09/10/1913468/0/en/Bondarenko-Acquires-16-2-Beneficial-Ownership-of-BriaCell-Therapeutics-Corp.html?f=22&fvtc=4&fvtv=53980Bondarenko Acquires 16.2% Beneficial Ownership of BriaCell Therapeutics Corp.2019-09-10T12:55:05Z<![CDATA[TORONTO, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 3,154,302 common shares (the “Shares”) of BriaCell Therapeutics Corp. (BCT-TSXV) (“BriaCell”). Bondarenko acquired the Shares through BriaCell’s previously-announced private placement which closed on September 9, 2019 at a price of $0.07 per Share for an aggregate purchase price of $220,801 (the “Acquisition”).]]>https://www.globenewswire.com/news-release/2019/05/17/1826919/0/en/Bondarenko-Acquires-14-48-Beneficial-Ownership-of-BriaCell-Therapeutics-Corp.html?f=22&fvtc=4&fvtv=53980Bondarenko Acquires 14.48% Beneficial Ownership of BriaCell Therapeutics Corp.2019-05-17T13:24:29Z<![CDATA[TORONTO, May 17, 2019 (GLOBE NEWSWIRE) -- Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 1,698,000 common shares (the “Shares”) of BriaCell Therapeutics Corp. (BCT-TSXV) (“BriaCell”). Bondarenko acquired the Shares through the facilities of the TSX Venture Exchange at an average purchase price of $0.083 per Share for an aggregate purchase price of $140,575 (the “Acquisition”) as disclosed on SEDI.ca.]]>https://www.globenewswire.com/news-release/2019/03/26/1767277/0/en/Jamieson-Bondarenko-Acquires-5-000-000-Common-Shares-of-BriaCell-Therapeutics-Corp.html?f=22&fvtc=4&fvtv=53980Jamieson Bondarenko Acquires 5,000,000 Common Shares of BriaCell Therapeutics Corp.2019-03-26T01:26:00Z<![CDATA[TORONTO, March 25, 2019 (GLOBE NEWSWIRE) -- Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 5,000,000 common shares (the “Shares”) of BriaCell Therapeutics Corp. (BCT-TSXV) (“BriaCell”). Bondarenko acquired the Shares through BriaCell’s previously-announced private placement which closed on March 25, 2019 at a price of $0.10 per Share for an aggregate purchase price of $500,000 (the “Acquisition”).]]>https://www.globenewswire.com/news-release/2019/02/13/1724275/0/en/Jamieson-Bondarenko-Acquires-11-0-Beneficial-Ownership-of-BriaCell-Therapeutics-Corp.html?f=22&fvtc=4&fvtv=53980Jamieson Bondarenko Acquires 11.0% Beneficial Ownership of BriaCell Therapeutics Corp.2019-02-13T00:57:01Z<![CDATA[TORONTO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Jamieson Bondarenko (“Bondarenko”) announced today that he has acquired an aggregate of 2,000,000 common shares (the “Shares”) of BriaCell Therapeutics Corp. (BCT-TSXV) (“BriaCell”). Bondarenko acquired the Shares through the facilities of the TSX Venture Exchange on February 12, 2019 at a price of $0.0975 per Share for an aggregate purchase price of $195,000 (the “Acquisition”).]]>